Jupiter Topco LLC Buys New Position in Aktis Oncology $AKTS

Jupiter Topco LLC bought a new stake in Aktis Oncology (NASDAQ:AKTS) during the second quarter, Holdings Channel.com reports. The fund bought 1,314,267 shares of the technology company’s stock, valued at approximately $42,359,000.

Several other institutional investors also recently added to or reduced their stakes in the business. State of Wyoming bought a new stake in shares of Aktis Oncology in the second quarter valued at approximately $32,000. Deutsche Bank AG increased its position in Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after acquiring an additional 6,942 shares during the period. Great Lakes Advisors LLC bought a new position in Aktis Oncology during the second quarter worth $1,406,000. The Manufacturers Life Insurance Company raised its stake in Aktis Oncology by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock valued at $1,548,000 after purchasing an additional 1,051 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Aktis Oncology by 14.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after purchasing an additional 6,349 shares during the last quarter. 28.84% of the stock is owned by institutional investors.

Insider Activity at Aktis Oncology

In other news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.30% of the company’s stock.

Aktis Oncology Trading Down 1.2%

Shares of NASDAQ AKTS opened at $26.18 on Friday. The firm has a market capitalization of $1.41 billion and a price-to-earnings ratio of -31.93. Aktis Oncology has a one year low of $14.72 and a one year high of $34.19. The business has a fifty day simple moving average of $25.78 and a 200 day simple moving average of $21.47.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. On average, research analysts anticipate that Aktis Oncology will post -1.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AKTS has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Raymond James Financial started coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. HC Wainwright lifted their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Wedbush started coverage on Aktis Oncology in a research note on Wednesday, August 19th. They set an “outperform” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.